<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7432271\results\search\testTrace\results.xml">
  <result pre="The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)" exact="infection" post="has rapidly spread worldwide and produced unprecedented social and"/>
  <result pre="are no Food and Drug Administration (FDA)-approved drugs for the" exact="treatment" post="of COVID-19, although remdesivir, an investigational antiviral drug, is"/>
  <result pre="has not been identified [23]. The initial step during SARS-CoV-2" exact="infection" post="is the binding of S to its host receptors,"/>
  <result pre="(IFN)-Î± and IFN-Î², determine the innate immune response to SARS-CoV-2" exact="infection" post="[35]. Pathogen associated molecular patterns (PAMPs) such as viral"/>
  <result pre="Toll-like receptors (TLR-) 3, 7/8 and 9 are responsible for" exact="detection" post="of SARS-CoV-2 [24]. These TLRs are mainly expressed in"/>
  <result pre="which have been reported to be overexpressed significantly in SARS-CoV-2" exact="infection" post="in association with â€œcytokine stormâ€� [37,38]. TI IFNs and"/>
  <result pre="CD4+ T cells are more susceptible than CD8+ cells to" exact="infection" post="by MERS-CoV and SARS-CoV [56]. During SARS-CoV-2 infection, a"/>
  <result pre="of IL-17 and related altered cytokines are highlighted in SARS-CoV-2" exact="infection" post="[57]. One of the important methods that SARS-CoV-2 may"/>
  <result pre="of innate immune cells. Thus, inhibiting C3a and C5a during" exact="infection" post="with MERS-CoV, SARS-CoV or SARS-CoV-2 could be introduced as"/>
  <result pre="morbidity of COVID-19 [70]. CRS is not specific to SARS-CoV-2" exact="infection" post="and has been demonstrated for MERS-CoV and SARS-CoV, as"/>
  <result pre="against human IL-6R [79,80]. It has been approved for the" exact="treatment" post="of rheumatoid arthritis and systemic juvenile idiopathic arthritis and"/>
  <result pre="allows health care providers to adjust and select the best" exact="treatment" post="option for vulnerable patients, reducing the risk of side"/>
  <result pre="stratify public health policies and guidelines to allow easing of" exact="social distancing" post="restrictions, while protecting the vulnerables. Finally, determining which comorbidities"/>
  <result pre="outcomes will help researchers to understand the pathophysiology of SARS-CoV-2" exact="infection" post="and its interactions with underlying chronic diseases. Early clinical"/>
  <result pre="of disease modifying drugs have been proposed for the specific" exact="treatment" post="of COVID-19 disease and will be discussed below. The"/>
  <result pre="Antivirals 8.1.1. Remdesivir Remdesivir (RDV) was originally developed as a" exact="treatment" post="for Ebola and Marburg virus infection and is a"/>
  <result pre="originally developed as a treatment for Ebola and Marburg virus" exact="infection" post="and is a promising candidate for treatment of COVID19."/>
  <result pre="and Marburg virus infection and is a promising candidate for" exact="treatment" post="of COVID19. RDV is an adenosine nucleotide analogue with"/>
  <result pre="cells has shown that remdesivir at low-micromolar concentrations blocks SARS-CoV-2" exact="infection" post="with high selectivity (half-maximal effective concentration (EC50), 0.77 Î¼M;"/>
  <result pre="SI &amp;gt; 129.87) [101]. Interestingly, remdesivir demonstrated promising results in" exact="treatment" post="of the first patient diagnosed with COVID-19 in the"/>
  <result pre="two structurally related protease inhibitor antiretroviral agents primarily used for" exact="treatment" post="of HIV-1 infection in adults and children over 2"/>
  <result pre="protease inhibitor antiretroviral agents primarily used for treatment of HIV-1" exact="infection" post="in adults and children over 2 years of age."/>
  <result pre="(CYP3A4) [109]. A study of six patients with confirmed COVID-19" exact="infection" post="in Korea and China showed a significant decrease in"/>
  <result pre="and Hong Kong to evaluate efficacy of LPV/r for the" exact="treatment" post="of COVID-19, either alone or in combination with other"/>
  <result pre="(FPV) is a guanine nucleic acid analogue approved for the" exact="treatment" post="of resistant strains of influenza [118]. Intracellular phosphoribosylation of"/>
  <result pre="of favipiravir plus interferon-Î± with LPV/r plus interferon-Î± for the" exact="treatment" post="of COVID-19. Favipiravir was associated with more rapid viral"/>
  <result pre="human origin, at considerably lower concentrations than with either single" exact="treatment" post="alone [128]. Similarly, the combination of IFN-Î±2b and ribavirin"/>
  <result pre="(EC50 of 109.5 ÂµM) are required to reduce the viral" exact="infection" post="and ribavirin is 100 times less potent than remdesivir"/>
  <result pre="efficacy of this compound, the administration of ribavirin for the" exact="treatment" post="of COVID-19 is not recommended. An ongoing trial in"/>
  <result pre="ribavirin and LPV/r in combination with interferon alpha-1b for SARS-CoV-2" exact="infection" post="[132]. 8.1.5. Arbidol Hydrochloride (Umifenovir) Arbidol (ARB; ethyl-6-bromo-4-[(dimethylamino) methyl]-5-hydroxy-1-methyl-2-[(phenylthio)methyl]-indole-3-carboxylate"/>
  <result pre="major glycoprotein on the surface of the virion, thereby preventing" exact="infection" post="[135]. For SARS-CoV, studies have shown direct antiviral effects"/>
  <result pre="[136]. In China, limited clinical experience with arbidol for COVID-19" exact="treatment" post="has been described. In one study from Wuhan in"/>
  <result pre="hospitalized patients with confirmed SARS-CoV-2 infection, 36 (53.7%) received arbidol" exact="treatment" post="for a median duration of 9 days and demonstrated"/>
  <result pre="investigating the efficacy of favipiravir compared with arbidol in the" exact="treatment" post="of COVID-19 patients, the clinical recovery rate at day"/>
  <result pre="4-(4-guanidinobenzoyloxy)-phenylacetate) is a synthetic serine protease inhibitor used for the" exact="treatment" post="of chronic pancreatitis, dystrophic epidermolysis, oral squamous cell carcinoma"/>
  <result pre="that camostat partially blocked SARS-CoV and human coronavirus NL63 (HCoV-NL63)" exact="infection" post="in HeLa cells expressing the ACE2 receptor and TMPRSS2"/>
  <result pre="[142]. Additionally, the effect of camostat mesylate in blocking SARS-CoV-2" exact="infection" post="of human lung Calu-3 cells has been demonstrated [143]."/>
  <result pre="clinical trial is evaluating the efficacy of camostat mesylate for" exact="treatment" post="of COVID-19 (NCT04353284), but more studies are needed to"/>
  <result pre="in Japan since 1986 that has been approved for the" exact="treatment" post="of inflammatory-related diseases such as pancreatitis [144,145]. Nafamostat is"/>
  <result pre="inhibitor of S-mediated membrane fusion of MERS-CoV and blocks MERS-CoV" exact="infection" post="in vitro [22]. The anti MERS-CoV activity of nafamostat"/>
  <result pre="of gabexate mesylate, nafamostat mesylate and camostat mesylate on SARS-CoV-2" exact="infection" post="and demonstrated that nafamostat mesylate inhibited S-mediated entry of"/>
  <result pre="proteases instead of viral protein inhibitors is that it avoids" exact="treatment" post="failure due to mutations of the target. Despite these"/>
  <result pre="in vitro data, the efficacy of nafamostat as a COVID-19" exact="treatment" post="needs to be tested in clinical trials. 8.2. Anti-Parasites"/>
  <result pre="Previous studies have reported the potential use of chloroquine for" exact="treatment" post="of SARS-CoV [150]. The potent efficacy of remdesivir and"/>
  <result pre="evaluated in Vero E6; chloroquine was effective in controlling SARS-CoV-2" exact="infection" post="in vitro with an EC50 at 48 h of"/>
  <result pre="the FDA announced the use of hydroxychloroquine and chloroquine for" exact="treatment" post="of hospitalized COVID-19 patients can cause serious heart rhythm"/>
  <result pre="are already registered in the Chinese clinical trial registry (http://www.chictr.org.cn)" exact="testing" post="the efficacy of chloroquine and hydroxychloroquine. In addition, hydroxychloroquine"/>
  <result pre="for SARS-CoV-2 infection. Recently the NIH guidelines panel for COVID-19" exact="treatment" post="recommended against the use of chloroquine or hydroxychloroquine for"/>
  <result pre="recommended against the use of chloroquine or hydroxychloroquine for the" exact="treatment" post="of COVID-19, except in a clinical trial. The panel"/>
  <result pre="chloroquine (600 mg twice daily for 10 days) for the" exact="treatment" post="of COVID-19 [165]. 8.2.2. Ivermectin Ivermectin is an FDA-approved"/>
  <result pre="an FDA-approved broad spectrum anti-parasitic agent mainly used in the" exact="treatment" post="of onchocerciasis, which shows anti-viral effects against HIV-1, simian"/>
  <result pre="humans [169]. Overall, the possible efficacy of ivermectin against SARS-CoV-2" exact="infection" post="needs data to support it. 9. Immunotherapy Several studies"/>
  <result pre="9. Immunotherapy Several studies have been undertaken to develop new" exact="treatment" post="strategies for viral infections and the use of immunotherapy"/>
  <result pre="two main categories of acquired artificial passive immunity against COVID-19:" exact="treatment" post="with monoclonal antibodies (mAbs) and convalescent plasma from people"/>
  <result pre="plasma was not successful for Ebola [175]. Patients with SARS-CoV-2" exact="infection" post="develop a serum antibody response (IgG) to different epitopes"/>
  <result pre="Passive antibody therapy is more effective as prophylaxis than for" exact="treatment" post="and in infected patients its effectiveness was higher when"/>
  <result pre="higher discharge rate (58.3% vs. 15.6%), including those who were" exact="polymerase chain reaction" post="(PCR) positive and seronegative for SARS-CoV at the time"/>
  <result pre="convalescent SARS patients to three health care workers with SARS" exact="infection" post="in Taiwan resulted in survival of all three patients,"/>
  <result pre="MERS patients [195]. For COVID-19, Shi et al. reported successful" exact="treatment" post="of a confirmed patient with advanced respiratory failure, shock"/>
  <result pre="[196]. They emphasized the importance of early initiation of PE" exact="treatment" post="and IVIG to avoid progression to ARDS and multi-organ"/>
  <result pre="receptor antagonist (recombinant humanized anti IL-6R monoclonal antibody) approved for" exact="treatment" post="of rheumatoid arthritis [202]. It is currently being evaluated"/>
  <result pre="biosimilar mAbs (Qletli) for their safety and efficacy in COVID-19" exact="treatment" post="in China (ChiCTR2000030089, ChiCTR2000030580). However, upper respiratory tract infections"/>
  <result pre="However, upper respiratory tract infections and reactivation of hepatitis B" exact="infection" post="are common and concerning side effects [203]. Baricitinib is"/>
  <result pre="orally administered, JAK antagonist monoclonal antibody used routinely for the" exact="treatment" post="of rheumatoid arthritis [204]. Although JAK blockers are considered"/>
  <result pre="April 2020 [206]. Ibalizumab is non-immunosuppressive, FDA approved for the" exact="treatment" post="of multidrug-resistant HIV in 2018 [207] and may be"/>
  <result pre="[208]. A clinical trial has been registered using camrelizumab for" exact="treatment" post="of critical COVID-19 patients in China [209]. Omalizumab is"/>
  <result pre="single dose of mAb targeting GM-CSF (mavrilimumab) to standard hospital" exact="treatment" post="improved clinical outcomes in patients with COVID-19 [211]. The"/>
  <result pre="antibodies can also be used to neutralize SARS-CoV-2, for both" exact="treatment" post="and prevention of COVID-19. Several neutralizing monoclonal antibodies against"/>
  <result pre="from memory B cells from an individual convalescing from SARS-CoV" exact="infection" post="are also capable of neutralizing SARS-CoV-2 [213]. By screening"/>
  <result pre="SARS-CoV infection are also capable of neutralizing SARS-CoV-2 [213]. By" exact="screening" post="hybridomas from immunized mice using pseudotyped vesicular stomatitis virus,"/>
  <result pre="mAb, which in cell culture was able to block SARS-CoV-2" exact="infection" post="[214]. In another study, four mAbs were isolated from"/>
  <result pre="al. reported antiviral activity of azithromycin against Influenza (H1N1) virus;" exact="treatment" post="prior to infection inhibited virus replication by blocking internalization"/>
  <result pre="activity of azithromycin against Influenza (H1N1) virus; treatment prior to" exact="infection" post="inhibited virus replication by blocking internalization into host cells,"/>
  <result pre="are two important aspects of the pathogenesis in severe SARS-CoV-2" exact="infection" post="[222]. However, a meta-analysis of previous observational studies revealed"/>
  <result pre="corticosteroids are likely to be used in critically ill patients," exact="treatment" post="was associated with increased mortality (Risk Ratio RR ="/>
  <result pre="(Risk Ratio RR = 2.11, p-value = 0.019), increased bacterial" exact="infection" post="(RR = 2.08, p &amp;lt; 0.001) and led to"/>
  <result pre="or twice daily, there was no significant association between corticosteroid" exact="treatment" post="and time to viral clearance or length of hospitalization"/>
  <result pre="by the Center for Disease Control and Prevention (CDC), corticosteroid" exact="treatment" post="is not recommended in confirmed COVID-19 infections except in"/>
  <result pre="10 days) can save lives in intubated COVID-19 patients. Dexamethasone" exact="treatment" post="reduced the 28-day mortality by one-third in intubated patients"/>
  <result pre="respiratory support [229,230]. Therefore, reflecting its benefit, the NIH COVID-19" exact="treatment" post="guidelines panel recommended administration of dexamethasone (6 mg/day for"/>
  <result pre="virus, SARS or MERS coronaviruses have been investigated for the" exact="treatment" post="of COVID-19, alone or in combination with other drugs"/>
  <result pre="or laboratory-confirmed COVID-19. Moreover, the NIH panel recommends remdesivir for" exact="treatment" post="of COVID-19 in patients who are on mechanical ventilation"/>
  <result pre="on mechanical ventilation or extracorporeal membrane oxygenation (ECMO) [2]. Dexamethasone" exact="treatment" post="showed promising results in reducing the 28-day mortality in"/>
  <result pre="hydroxychloroquine, Lopinavir/ritonavir or non-SARS-CoV-2-specific intravenous immune globulin (IVIG) for the" exact="treatment" post="of COVID-19, except in a clinical trial. Furthermore, NIH"/>
  <result pre="globulin or Interleukin-6 inhibitors (e.g., sarilumab, siltuximab, tocilizumab) for the" exact="treatment" post="of COVID-19, due to insufficient data. The constantly changing"/>
  <result pre="intravenous immunoglobulin PE plasma exchange ICU intensive care unit PCR" exact="polymerase chain reaction" post="qRT-PCR quantitative reverse transcriptase PCR WHO World Health Organization"/>
  <result pre="cell entry by SARS-CoV-2Antivir. Res.202017710475910.1016/j.antiviral.2020.10475932130973 15.WangH.LiX.LiT.ZhangS.WangL.WuX.LiuJ.The genetic sequence, origin, and" exact="diagnosis" post="of SARS-CoV-2Eur. J. Clin. Microbiol. Infect. Dis.2020110.1007/s10096-020-03899-432333222 16.WallsA.C.ParkY.J.TortoriciM.A.WallA.McGuireA.T.VeeslerD.Structure, Function,"/>
  <result pre="with COVID-19J. Infect.202081e6e1210.1016/j.jinf.2020.04.00232283162 35.SallardE.LescureF.-X.YazdanpanahY.MentreF.Peiffer-SmadjaN.AderF.BouadmaL.PoissyJ.TimsitJ.-F.LinaB.et al.Type 1 interferons as a potential" exact="treatment" post="against COVID-19Antivir. Res.202017810479110.1016/j.antiviral.2020.10479132275914 36.Blanco-MeloD.Nilsson-PayantB.E.LiuW.-C.UhlS.HoaglandD.MÃ¸llerR.JordanT.X.OishiK.PanisM.SachsD.et al.Imbalanced Host Response to SARS-CoV-2"/>
  <result pre="the Novel Corona Viral Infection: A ConsiderationAsian J. Immunol.202031625 41.RatajczakM.Z.KuciaM.SARS-CoV-2" exact="infection" post="and overactivation of Nlrp3 inflammasome as a trigger of"/>
  <result pre="of protective immunity against severe acute respiratory syndrome coronavirus (SARS-CoV)" exact="infection" post="using highly attenuated recombinant vaccinia virus DIsVirology200635136838010.1016/j.virol.2006.03.02016678878 45.BhattacharyaM.SharmaA.R.PatraP.GhoshP.SharmaG.PatraB.C.LeeS.-S.ChakrabortyC.Development of"/>
  <result pre="cytokine at the crossroads of autoimmunityCurr. Opin. Immunol.20185591410.1016/j.coi.2018.09.00230248523 80.XuX.HanM.LiT.SunW.WangD.FuB.ZhouY.ZhengX.YangY.LiX.et al.Effective" exact="treatment" post="of severe COVID-19 patients with tocilizumabProc. Natl. Acad. Sci."/>
  <result pre="double-blind, placebo-controlled, multicentre trialLancet20203951569157810.1016/S0140-6736(20)31022-932423584 107.ChuC.ChengV.C.C.HungI.F.N.WongM.M.L.ChanK.KaoR.Y.T.PoonL.L.WongC.L.P.GuanY.PeirisJ.S.M.et al.Role of lopinavir/ritonavir in the" exact="treatment" post="of SARS: Initial virological and clinical findingsThorax20045925225610.1136/thorax.2003.01265814985565 108.WuC.LiuY.YangY.ZhangP.ZhongW.WangY.WangQ.XuY.LiM.LiX.et al.Analysis"/>
  <result pre="disease 2019 in Korea: The application of lopinavir/ritonavir for the" exact="treatment" post="of COVID-19 pneumonia monitored by quantitative RT-PCRJ. Korean Med."/>
  <result pre="Antimicrob. Agents20205510593810.1016/j.ijantimicag.2020.10593832171740 148.VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.SeidahN.G.NicholS.T.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol. J.200526910.1186/1743-422X-2-6916115318 149.SinghA.K.SinghA.ShaikhA.SinghR.MisraA.Chloroquine and hydroxychloroquine in the treatment"/>
  <result pre="coronavirus infection and spreadVirol. J.200526910.1186/1743-422X-2-6916115318 149.SinghA.K.SinghA.ShaikhA.SinghR.MisraA.Chloroquine and hydroxychloroquine in the" exact="treatment" post="of COVID-19 with or without diabetes: A systematic search"/>
  <result pre="acidification by chloroquine analogs as a promising strategy for the" exact="treatment" post="of emerging viral diseasesPharmacol. Res. Perspect.20175e0029310.1002/prp2.29328596841 156.BiotC.DaherW.ChavainN.FandeurT.KhalifeJ.DiveD.De ClercqE.Design and"/>
  <result pre="2 (SARS-CoV-2)Clin. Infect. Dis.202010.1093/cid/ciaa237 158.GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.et al.Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: Results of an open-label non-randomized clinical trialInt."/>
  <result pre="transport importin Î±/Î²1 heterodimerAntivir. Res.202017710476010.1016/j.antiviral.2020.10476032135219 169.MomekovG.MomekovaD.Ivermectin as a potential COVID-19" exact="treatment" post="from the pharmacokinetic point of view: Antiviral levels are"/>
  <result pre="dosing regimensBiotechnol. Biotechnol. Equip.20203446947410.1080/13102818.2020.1775118 170.BeigelJ.H.Polyclonal and monoclonal antibodies for the" exact="treatment" post="of influenzaCurr. Opin. Infect. Dis.20183152753410.1097/QCO.000000000000049930299360 171.MaranoG.VaglioS.PupellaS.FaccoG.CatalanoL.LiumbrunoG.M.GrazziniG.Convalescent plasma: New evidence"/>
  <result pre="J. Med.20121251036.e11036.e810.1016/j.amjmed.2012.01.02322608788 193.StockmanL.J.BellamyR.GarnerP.SARS: Systematic Review of Treatment EffectsPLoS Med.20063e34310.1371/journal.pmed.003034316968120 194.MustafaS.BalkhyH.GabereM.N.Current" exact="treatment" post="options and the role of peptides as potential therapeutic"/>
  <result pre="SeoY.ChoiJ.-P.ShinH.-S.TeamR.R.Antiviral Treatment Guidelines for Middle East Respiratory SyndromeInfect. Chemother.20154721222210.3947/ic.2015.47.3.21226483999 196.ShiH.ZhouC.HeP.HuangS.DuanY.WangX.LinK.ZhouC.ZhangX.ZhaY.Successful" exact="treatment" post="of plasma exchange followed by intravenous immunogloblin in a"/>
  <result pre="Pac. J. Allergy Immunol.202038101810.12932/AP-200220-077332134278 200.FuB.XuX.WeiH.Why tocilizumab could be an effective" exact="treatment" post="for severe COVID-19?J. Transl. Med.2020181510.1186/s12967-020-02339-331900168 201.DuY.-X.ChenX.-P.Favipiravir: Pharmacokinetics and Concerns"/>
  <result pre="meta-analysesRMD Open20195e00079810.1136/rmdopen-2018-00079830886733 203.BerkhoutL.C.Lâ€™AmiM.J.RuwaardJ.HartM.H.HeerP.O.-D.BloemK.NurmohamedM.T.Van VollenhovenR.F.BoersM.AlvarezD.F.et al.Dynamics of circulating TNF during adalimumab" exact="treatment" post="using a drug-tolerant TNF assaySci. Transl. Med.201911eaat335610.1126/scitranslmed.aat335630700574 204.MarkhamA.Baricitinib: First"/>
  <result pre="219.TranD.H.SugamataR.HiroseT.SuzukiS.NoguchiY.SugawaraA.ItoF.YamamotoT.KawachiS.AkagawaK.S.et al.Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A(H1N1)pdm09 virus" exact="infection" post="by interfering with virus internalization processJ. Antibiot.20197275976810.1038/s41429-019-0204-x31300721 220.BarnesP.J.How corticosteroids"/>
  <result pre="SyndromeAm. J. Respir. Crit. Care Med.201819775776710.1164/rccm.201706-1172OC29161116 225.YangZ.LiuJ.ZhouY.ZhaoX.ZhaoQ.LiuJ.The effect of corticosteroid" exact="treatment" post="on patients with coronavirus infection: A systematic review and"/>
  <result pre="with coronavirus infection: A systematic review and meta-analysisJ. Infect.202081e13e2010.1016/j.jinf.2020.03.06232283144 226.ZhaL.LiS.PanL.TefsenB.LiY.FrenchN.ChenL.YangG.VillanuevaE.V.Corticosteroid" exact="treatment" post="of patients with coronavirus disease 2019 (COVID -19)Med. J."/>
  <result pre="Infect.202010.1016/j.jinf.2020.03.039 228.World Health Organization Clinical management of severe acute respiratory" exact="infection" post="(SARI) when COVID-19 disease is suspected. Interim guidancePediatr. Med."/>
  <result pre="Severe Acute Respiratory Syndrome CoronavirusJ. Virol.2005791966196910.1128/jvi.79.3.1966-1969.200515650225 233.KeyaertsE.VijgenL.ChenL.MaesP.HedenstiernaG.Van RanstM.Inhibition of SARS-coronavirus" exact="infection" post="in vitro by S-nitroso-N-acetylpenicillamine, a nitric oxide donor compoundInt."/>
  <result pre="donor compoundInt. J. Infect. Dis.2004822322610.1016/j.ijid.2004.04.01215234326 234.DellingerR.P.TrzeciakS.CrinerG.ZimmermanJ.L.TaylorR.W.UsanskyH.YoungJ.GoldsteinB.Association between inhaled nitric oxide" exact="treatment" post="and long-term pulmonary function in survivors of acute respiratory"/>
  <result pre="cross. ijms-21-05559-t001_Table 1Table 1 List of available drugs targeting SARS-CoV-2" exact="infection" post="and their effective dosage. Name of Medicine Target Classification"/>
 </snippets>
</snippetsTree>
